nodes	percent_of_prediction	percent_of_DWPC	metapath
Valproic Acid—UGT2B7—Epirubicin—liver cancer	0.148	0.285	CbGbCtD
Valproic Acid—UGT1A9—Sorafenib—liver cancer	0.137	0.264	CbGbCtD
Valproic Acid—CYP2B6—Sorafenib—liver cancer	0.0434	0.0835	CbGbCtD
Valproic Acid—CYP3A5—Sorafenib—liver cancer	0.0342	0.0658	CbGbCtD
Valproic Acid—CYP2C8—Sorafenib—liver cancer	0.0328	0.0633	CbGbCtD
Valproic Acid—CYP2C19—Sorafenib—liver cancer	0.0275	0.0531	CbGbCtD
Valproic Acid—CYP2B6—Doxorubicin—liver cancer	0.0263	0.0507	CbGbCtD
Valproic Acid—CYP1A2—Sorafenib—liver cancer	0.0254	0.049	CbGbCtD
Valproic Acid—CYP2C9—Sorafenib—liver cancer	0.0229	0.0441	CbGbCtD
Valproic Acid—CYP3A4—Sorafenib—liver cancer	0.0133	0.0257	CbGbCtD
Valproic Acid—CYP3A4—Doxorubicin—liver cancer	0.00808	0.0156	CbGbCtD
Valproic Acid—UGT2B15—gall bladder—liver cancer	0.0038	0.164	CbGeAlD
Valproic Acid—UGT1A10—liver—liver cancer	0.00168	0.0725	CbGeAlD
Valproic Acid—UGT1A6—liver—liver cancer	0.00156	0.0674	CbGeAlD
Valproic Acid—UGT1A8—liver—liver cancer	0.00133	0.0573	CbGeAlD
Valproic Acid—OGDH—liver—liver cancer	0.00124	0.0533	CbGeAlD
Valproic Acid—HDAC2—embryo—liver cancer	0.0012	0.0519	CbGeAlD
Valproic Acid—UGT1A3—liver—liver cancer	0.00118	0.0511	CbGeAlD
Valproic Acid—UGT2B15—liver—liver cancer	0.00111	0.048	CbGeAlD
Valproic Acid—UGT1A4—liver—liver cancer	0.00101	0.0434	CbGeAlD
Valproic Acid—ACADSB—liver—liver cancer	0.000982	0.0423	CbGeAlD
Valproic Acid—ALDH5A1—liver—liver cancer	0.000864	0.0372	CbGeAlD
Valproic Acid—UGT1A9—liver—liver cancer	0.000844	0.0364	CbGeAlD
Valproic Acid—ABAT—liver—liver cancer	0.000739	0.0319	CbGeAlD
Valproic Acid—CYP2C18—liver—liver cancer	0.000738	0.0318	CbGeAlD
Valproic Acid—UGT2B7—liver—liver cancer	0.00068	0.0293	CbGeAlD
Valproic Acid—SLC22A7—liver—liver cancer	0.000647	0.0279	CbGeAlD
Valproic Acid—HDAC2—liver—liver cancer	0.000557	0.024	CbGeAlD
Valproic Acid—SLC16A1—liver—liver cancer	0.000495	0.0213	CbGeAlD
Valproic Acid—CYP2A6—liver—liver cancer	0.000488	0.021	CbGeAlD
Valproic Acid—Increased appetite—Doxorubicin—liver cancer	0.000317	0.00172	CcSEcCtD
Valproic Acid—Affect lability—Epirubicin—liver cancer	0.000317	0.00171	CcSEcCtD
Valproic Acid—Hypersensitivity—Sorafenib—liver cancer	0.000315	0.00171	CcSEcCtD
Valproic Acid—CYP2C19—liver—liver cancer	0.000314	0.0135	CbGeAlD
Valproic Acid—Dermatitis bullous—Doxorubicin—liver cancer	0.000311	0.00169	CcSEcCtD
Valproic Acid—Face oedema—Epirubicin—liver cancer	0.000311	0.00168	CcSEcCtD
Valproic Acid—Asthenia—Sorafenib—liver cancer	0.000307	0.00166	CcSEcCtD
Valproic Acid—Mood swings—Epirubicin—liver cancer	0.000305	0.00165	CcSEcCtD
Valproic Acid—Lethargy—Doxorubicin—liver cancer	0.000304	0.00164	CcSEcCtD
Valproic Acid—Pruritus—Sorafenib—liver cancer	0.000303	0.00164	CcSEcCtD
Valproic Acid—Ataxia—Epirubicin—liver cancer	0.000302	0.00164	CcSEcCtD
Valproic Acid—Hyponatraemia—Doxorubicin—liver cancer	0.000299	0.00162	CcSEcCtD
Valproic Acid—Osteoarthritis—Doxorubicin—liver cancer	0.000298	0.00161	CcSEcCtD
Valproic Acid—Diplopia—Doxorubicin—liver cancer	0.000298	0.00161	CcSEcCtD
Valproic Acid—Dry skin—Epirubicin—liver cancer	0.000295	0.0016	CcSEcCtD
Valproic Acid—Abdominal pain upper—Epirubicin—liver cancer	0.000294	0.00159	CcSEcCtD
Valproic Acid—Orthostatic hypotension—Epirubicin—liver cancer	0.000294	0.00159	CcSEcCtD
Valproic Acid—Affect lability—Doxorubicin—liver cancer	0.000293	0.00159	CcSEcCtD
Valproic Acid—Diarrhoea—Sorafenib—liver cancer	0.000293	0.00159	CcSEcCtD
Valproic Acid—Breast disorder—Epirubicin—liver cancer	0.000291	0.00157	CcSEcCtD
Valproic Acid—Toxic epidermal necrolysis—Epirubicin—liver cancer	0.00029	0.00157	CcSEcCtD
Valproic Acid—Aspartate aminotransferase increased—Epirubicin—liver cancer	0.00029	0.00157	CcSEcCtD
Valproic Acid—Face oedema—Doxorubicin—liver cancer	0.000287	0.00156	CcSEcCtD
Valproic Acid—Alanine aminotransferase increased—Epirubicin—liver cancer	0.000284	0.00154	CcSEcCtD
Valproic Acid—Muscular weakness—Epirubicin—liver cancer	0.000284	0.00154	CcSEcCtD
Valproic Acid—Dizziness—Sorafenib—liver cancer	0.000283	0.00153	CcSEcCtD
Valproic Acid—SLC22A5—liver—liver cancer	0.000283	0.0122	CbGeAlD
Valproic Acid—Mood swings—Doxorubicin—liver cancer	0.000282	0.00153	CcSEcCtD
Valproic Acid—Ataxia—Doxorubicin—liver cancer	0.00028	0.00152	CcSEcCtD
Valproic Acid—Influenza—Epirubicin—liver cancer	0.000278	0.00151	CcSEcCtD
Valproic Acid—Dysphagia—Epirubicin—liver cancer	0.000278	0.00151	CcSEcCtD
Valproic Acid—Eosinophilia—Epirubicin—liver cancer	0.000275	0.00149	CcSEcCtD
Valproic Acid—CYP2C8—liver—liver cancer	0.000274	0.0118	CbGeAlD
Valproic Acid—Dry skin—Doxorubicin—liver cancer	0.000273	0.00148	CcSEcCtD
Valproic Acid—Pancreatitis—Epirubicin—liver cancer	0.000273	0.00148	CcSEcCtD
Valproic Acid—Vomiting—Sorafenib—liver cancer	0.000272	0.00147	CcSEcCtD
Valproic Acid—Orthostatic hypotension—Doxorubicin—liver cancer	0.000272	0.00147	CcSEcCtD
Valproic Acid—Abdominal pain upper—Doxorubicin—liver cancer	0.000272	0.00147	CcSEcCtD
Valproic Acid—Rash—Sorafenib—liver cancer	0.00027	0.00146	CcSEcCtD
Valproic Acid—Dermatitis—Sorafenib—liver cancer	0.000269	0.00146	CcSEcCtD
Valproic Acid—Breast disorder—Doxorubicin—liver cancer	0.000269	0.00146	CcSEcCtD
Valproic Acid—Aspartate aminotransferase increased—Doxorubicin—liver cancer	0.000268	0.00145	CcSEcCtD
Valproic Acid—Toxic epidermal necrolysis—Doxorubicin—liver cancer	0.000268	0.00145	CcSEcCtD
Valproic Acid—Headache—Sorafenib—liver cancer	0.000268	0.00145	CcSEcCtD
Valproic Acid—Bronchitis—Epirubicin—liver cancer	0.000267	0.00145	CcSEcCtD
Valproic Acid—Pancytopenia—Epirubicin—liver cancer	0.000264	0.00143	CcSEcCtD
Valproic Acid—Alanine aminotransferase increased—Doxorubicin—liver cancer	0.000263	0.00142	CcSEcCtD
Valproic Acid—Muscular weakness—Doxorubicin—liver cancer	0.000263	0.00142	CcSEcCtD
Valproic Acid—Dysuria—Epirubicin—liver cancer	0.00026	0.00141	CcSEcCtD
Valproic Acid—Neutropenia—Epirubicin—liver cancer	0.00026	0.00141	CcSEcCtD
Valproic Acid—Dysphagia—Doxorubicin—liver cancer	0.000257	0.00139	CcSEcCtD
Valproic Acid—Influenza—Doxorubicin—liver cancer	0.000257	0.00139	CcSEcCtD
Valproic Acid—Pollakiuria—Epirubicin—liver cancer	0.000257	0.00139	CcSEcCtD
Valproic Acid—CYP1A2—liver—liver cancer	0.000256	0.011	CbGeAlD
Valproic Acid—Eosinophilia—Doxorubicin—liver cancer	0.000255	0.00138	CcSEcCtD
Valproic Acid—Nausea—Sorafenib—liver cancer	0.000254	0.00138	CcSEcCtD
Valproic Acid—Photosensitivity reaction—Epirubicin—liver cancer	0.000254	0.00137	CcSEcCtD
Valproic Acid—Weight increased—Epirubicin—liver cancer	0.000253	0.00137	CcSEcCtD
Valproic Acid—Pancreatitis—Doxorubicin—liver cancer	0.000252	0.00137	CcSEcCtD
Valproic Acid—Weight decreased—Epirubicin—liver cancer	0.000252	0.00136	CcSEcCtD
Valproic Acid—Pneumonia—Epirubicin—liver cancer	0.000249	0.00135	CcSEcCtD
Valproic Acid—Drowsiness—Epirubicin—liver cancer	0.000248	0.00134	CcSEcCtD
Valproic Acid—Bronchitis—Doxorubicin—liver cancer	0.000247	0.00134	CcSEcCtD
Valproic Acid—CYP3A5—liver—liver cancer	0.000247	0.0106	CbGeAlD
Valproic Acid—Stevens-Johnson syndrome—Epirubicin—liver cancer	0.000246	0.00133	CcSEcCtD
Valproic Acid—CYP2B6—liver—liver cancer	0.000246	0.0106	CbGeAlD
Valproic Acid—Pancytopenia—Doxorubicin—liver cancer	0.000244	0.00132	CcSEcCtD
Valproic Acid—CYP2C9—liver—liver cancer	0.000243	0.0105	CbGeAlD
Valproic Acid—Stomatitis—Epirubicin—liver cancer	0.000242	0.00131	CcSEcCtD
Valproic Acid—Conjunctivitis—Epirubicin—liver cancer	0.000241	0.00131	CcSEcCtD
Valproic Acid—Urinary tract infection—Epirubicin—liver cancer	0.000241	0.00131	CcSEcCtD
Valproic Acid—Neutropenia—Doxorubicin—liver cancer	0.000241	0.0013	CcSEcCtD
Valproic Acid—Dysuria—Doxorubicin—liver cancer	0.000241	0.0013	CcSEcCtD
Valproic Acid—Sweating—Epirubicin—liver cancer	0.000238	0.00129	CcSEcCtD
Valproic Acid—Pollakiuria—Doxorubicin—liver cancer	0.000238	0.00129	CcSEcCtD
Valproic Acid—Photosensitivity reaction—Doxorubicin—liver cancer	0.000235	0.00127	CcSEcCtD
Valproic Acid—Hepatobiliary disease—Epirubicin—liver cancer	0.000234	0.00127	CcSEcCtD
Valproic Acid—Weight increased—Doxorubicin—liver cancer	0.000234	0.00127	CcSEcCtD
Valproic Acid—Epistaxis—Epirubicin—liver cancer	0.000234	0.00127	CcSEcCtD
Valproic Acid—Weight decreased—Doxorubicin—liver cancer	0.000233	0.00126	CcSEcCtD
Valproic Acid—Sinusitis—Epirubicin—liver cancer	0.000233	0.00126	CcSEcCtD
Valproic Acid—Agranulocytosis—Epirubicin—liver cancer	0.000231	0.00125	CcSEcCtD
Valproic Acid—Pneumonia—Doxorubicin—liver cancer	0.000231	0.00125	CcSEcCtD
Valproic Acid—Drowsiness—Doxorubicin—liver cancer	0.000229	0.00124	CcSEcCtD
Valproic Acid—Stevens-Johnson syndrome—Doxorubicin—liver cancer	0.000227	0.00123	CcSEcCtD
Valproic Acid—Bradycardia—Epirubicin—liver cancer	0.000227	0.00123	CcSEcCtD
Valproic Acid—Haemoglobin—Epirubicin—liver cancer	0.000224	0.00121	CcSEcCtD
Valproic Acid—Stomatitis—Doxorubicin—liver cancer	0.000224	0.00121	CcSEcCtD
Valproic Acid—Rhinitis—Epirubicin—liver cancer	0.000223	0.00121	CcSEcCtD
Valproic Acid—Conjunctivitis—Doxorubicin—liver cancer	0.000223	0.00121	CcSEcCtD
Valproic Acid—Urinary tract infection—Doxorubicin—liver cancer	0.000223	0.00121	CcSEcCtD
Valproic Acid—Haemorrhage—Epirubicin—liver cancer	0.000223	0.00121	CcSEcCtD
Valproic Acid—Hypoaesthesia—Epirubicin—liver cancer	0.000221	0.0012	CcSEcCtD
Valproic Acid—Pharyngitis—Epirubicin—liver cancer	0.000221	0.0012	CcSEcCtD
Valproic Acid—Sweating—Doxorubicin—liver cancer	0.00022	0.00119	CcSEcCtD
Valproic Acid—Urinary tract disorder—Epirubicin—liver cancer	0.00022	0.00119	CcSEcCtD
Valproic Acid—Oedema peripheral—Epirubicin—liver cancer	0.000219	0.00119	CcSEcCtD
Valproic Acid—Connective tissue disorder—Epirubicin—liver cancer	0.000219	0.00118	CcSEcCtD
Valproic Acid—Urethral disorder—Epirubicin—liver cancer	0.000218	0.00118	CcSEcCtD
Valproic Acid—Hepatobiliary disease—Doxorubicin—liver cancer	0.000217	0.00117	CcSEcCtD
Valproic Acid—Epistaxis—Doxorubicin—liver cancer	0.000216	0.00117	CcSEcCtD
Valproic Acid—Sinusitis—Doxorubicin—liver cancer	0.000215	0.00117	CcSEcCtD
Valproic Acid—Visual impairment—Epirubicin—liver cancer	0.000214	0.00116	CcSEcCtD
Valproic Acid—Agranulocytosis—Doxorubicin—liver cancer	0.000214	0.00116	CcSEcCtD
Valproic Acid—Erythema multiforme—Epirubicin—liver cancer	0.00021	0.00114	CcSEcCtD
Valproic Acid—Bradycardia—Doxorubicin—liver cancer	0.00021	0.00114	CcSEcCtD
Valproic Acid—Eye disorder—Epirubicin—liver cancer	0.000208	0.00113	CcSEcCtD
Valproic Acid—Tinnitus—Epirubicin—liver cancer	0.000207	0.00112	CcSEcCtD
Valproic Acid—Haemoglobin—Doxorubicin—liver cancer	0.000207	0.00112	CcSEcCtD
Valproic Acid—Rhinitis—Doxorubicin—liver cancer	0.000206	0.00112	CcSEcCtD
Valproic Acid—Haemorrhage—Doxorubicin—liver cancer	0.000206	0.00112	CcSEcCtD
Valproic Acid—Hypoaesthesia—Doxorubicin—liver cancer	0.000205	0.00111	CcSEcCtD
Valproic Acid—Pharyngitis—Doxorubicin—liver cancer	0.000204	0.00111	CcSEcCtD
Valproic Acid—Urinary tract disorder—Doxorubicin—liver cancer	0.000203	0.0011	CcSEcCtD
Valproic Acid—Oedema peripheral—Doxorubicin—liver cancer	0.000203	0.0011	CcSEcCtD
Valproic Acid—Connective tissue disorder—Doxorubicin—liver cancer	0.000202	0.0011	CcSEcCtD
Valproic Acid—Angiopathy—Epirubicin—liver cancer	0.000202	0.00109	CcSEcCtD
Valproic Acid—Urethral disorder—Doxorubicin—liver cancer	0.000202	0.00109	CcSEcCtD
Valproic Acid—Immune system disorder—Epirubicin—liver cancer	0.000201	0.00109	CcSEcCtD
Valproic Acid—Mediastinal disorder—Epirubicin—liver cancer	0.000201	0.00109	CcSEcCtD
Valproic Acid—Chills—Epirubicin—liver cancer	0.0002	0.00108	CcSEcCtD
Valproic Acid—Arrhythmia—Epirubicin—liver cancer	0.000199	0.00108	CcSEcCtD
Valproic Acid—Visual impairment—Doxorubicin—liver cancer	0.000198	0.00107	CcSEcCtD
Valproic Acid—Alopecia—Epirubicin—liver cancer	0.000197	0.00107	CcSEcCtD
Valproic Acid—Mental disorder—Epirubicin—liver cancer	0.000195	0.00106	CcSEcCtD
Valproic Acid—Erythema multiforme—Doxorubicin—liver cancer	0.000195	0.00105	CcSEcCtD
Valproic Acid—Malnutrition—Epirubicin—liver cancer	0.000194	0.00105	CcSEcCtD
Valproic Acid—Eye disorder—Doxorubicin—liver cancer	0.000192	0.00104	CcSEcCtD
Valproic Acid—Tinnitus—Doxorubicin—liver cancer	0.000192	0.00104	CcSEcCtD
Valproic Acid—Flatulence—Epirubicin—liver cancer	0.000191	0.00103	CcSEcCtD
Valproic Acid—Tension—Epirubicin—liver cancer	0.00019	0.00103	CcSEcCtD
Valproic Acid—Dysgeusia—Epirubicin—liver cancer	0.00019	0.00103	CcSEcCtD
Valproic Acid—Nervousness—Epirubicin—liver cancer	0.000188	0.00102	CcSEcCtD
Valproic Acid—Back pain—Epirubicin—liver cancer	0.000187	0.00101	CcSEcCtD
Valproic Acid—Angiopathy—Doxorubicin—liver cancer	0.000187	0.00101	CcSEcCtD
Valproic Acid—Muscle spasms—Epirubicin—liver cancer	0.000186	0.00101	CcSEcCtD
Valproic Acid—Immune system disorder—Doxorubicin—liver cancer	0.000186	0.00101	CcSEcCtD
Valproic Acid—Mediastinal disorder—Doxorubicin—liver cancer	0.000186	0.00101	CcSEcCtD
Valproic Acid—CYP3A4—liver—liver cancer	0.000185	0.00799	CbGeAlD
Valproic Acid—Chills—Doxorubicin—liver cancer	0.000185	0.001	CcSEcCtD
Valproic Acid—Arrhythmia—Doxorubicin—liver cancer	0.000184	0.000996	CcSEcCtD
Valproic Acid—Vision blurred—Epirubicin—liver cancer	0.000183	0.000989	CcSEcCtD
Valproic Acid—Alopecia—Doxorubicin—liver cancer	0.000182	0.000985	CcSEcCtD
Valproic Acid—Mental disorder—Doxorubicin—liver cancer	0.00018	0.000977	CcSEcCtD
Valproic Acid—Ill-defined disorder—Epirubicin—liver cancer	0.00018	0.000973	CcSEcCtD
Valproic Acid—Malnutrition—Doxorubicin—liver cancer	0.000179	0.000971	CcSEcCtD
Valproic Acid—Anaemia—Epirubicin—liver cancer	0.000179	0.00097	CcSEcCtD
Valproic Acid—Agitation—Epirubicin—liver cancer	0.000178	0.000964	CcSEcCtD
Valproic Acid—Flatulence—Doxorubicin—liver cancer	0.000177	0.000957	CcSEcCtD
Valproic Acid—Tension—Doxorubicin—liver cancer	0.000176	0.000953	CcSEcCtD
Valproic Acid—Dysgeusia—Doxorubicin—liver cancer	0.000176	0.000951	CcSEcCtD
Valproic Acid—Malaise—Epirubicin—liver cancer	0.000175	0.000946	CcSEcCtD
Valproic Acid—Nervousness—Doxorubicin—liver cancer	0.000174	0.000943	CcSEcCtD
Valproic Acid—Vertigo—Epirubicin—liver cancer	0.000174	0.000943	CcSEcCtD
Valproic Acid—Leukopenia—Epirubicin—liver cancer	0.000173	0.000939	CcSEcCtD
Valproic Acid—Back pain—Doxorubicin—liver cancer	0.000173	0.000939	CcSEcCtD
Valproic Acid—Muscle spasms—Doxorubicin—liver cancer	0.000172	0.000933	CcSEcCtD
Valproic Acid—Palpitations—Epirubicin—liver cancer	0.000171	0.000927	CcSEcCtD
Valproic Acid—Cough—Epirubicin—liver cancer	0.000169	0.000916	CcSEcCtD
Valproic Acid—Vision blurred—Doxorubicin—liver cancer	0.000169	0.000915	CcSEcCtD
Valproic Acid—Hypertension—Epirubicin—liver cancer	0.000167	0.000906	CcSEcCtD
Valproic Acid—Ill-defined disorder—Doxorubicin—liver cancer	0.000166	0.000901	CcSEcCtD
Valproic Acid—Anaemia—Doxorubicin—liver cancer	0.000166	0.000897	CcSEcCtD
Valproic Acid—Arthralgia—Epirubicin—liver cancer	0.000165	0.000893	CcSEcCtD
Valproic Acid—Chest pain—Epirubicin—liver cancer	0.000165	0.000893	CcSEcCtD
Valproic Acid—Myalgia—Epirubicin—liver cancer	0.000165	0.000893	CcSEcCtD
Valproic Acid—Agitation—Doxorubicin—liver cancer	0.000165	0.000892	CcSEcCtD
Valproic Acid—Anxiety—Epirubicin—liver cancer	0.000164	0.00089	CcSEcCtD
Valproic Acid—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—liver cancer	0.000164	0.000887	CcSEcCtD
Valproic Acid—Discomfort—Epirubicin—liver cancer	0.000163	0.000883	CcSEcCtD
Valproic Acid—Malaise—Doxorubicin—liver cancer	0.000162	0.000875	CcSEcCtD
Valproic Acid—Dry mouth—Epirubicin—liver cancer	0.000161	0.000874	CcSEcCtD
Valproic Acid—Vertigo—Doxorubicin—liver cancer	0.000161	0.000872	CcSEcCtD
Valproic Acid—Leukopenia—Doxorubicin—liver cancer	0.00016	0.000869	CcSEcCtD
Valproic Acid—Confusional state—Epirubicin—liver cancer	0.000159	0.000863	CcSEcCtD
Valproic Acid—Palpitations—Doxorubicin—liver cancer	0.000158	0.000858	CcSEcCtD
Valproic Acid—Oedema—Epirubicin—liver cancer	0.000158	0.000856	CcSEcCtD
Valproic Acid—Anaphylactic shock—Epirubicin—liver cancer	0.000158	0.000856	CcSEcCtD
Valproic Acid—Infection—Epirubicin—liver cancer	0.000157	0.000851	CcSEcCtD
Valproic Acid—Cough—Doxorubicin—liver cancer	0.000156	0.000847	CcSEcCtD
Valproic Acid—Nervous system disorder—Epirubicin—liver cancer	0.000155	0.00084	CcSEcCtD
Valproic Acid—Thrombocytopenia—Epirubicin—liver cancer	0.000155	0.000838	CcSEcCtD
Valproic Acid—Hypertension—Doxorubicin—liver cancer	0.000155	0.000838	CcSEcCtD
Valproic Acid—Tachycardia—Epirubicin—liver cancer	0.000154	0.000836	CcSEcCtD
Valproic Acid—Skin disorder—Epirubicin—liver cancer	0.000154	0.000832	CcSEcCtD
Valproic Acid—Hyperhidrosis—Epirubicin—liver cancer	0.000153	0.000828	CcSEcCtD
Valproic Acid—Arthralgia—Doxorubicin—liver cancer	0.000153	0.000826	CcSEcCtD
Valproic Acid—Chest pain—Doxorubicin—liver cancer	0.000153	0.000826	CcSEcCtD
Valproic Acid—Myalgia—Doxorubicin—liver cancer	0.000153	0.000826	CcSEcCtD
Valproic Acid—Anxiety—Doxorubicin—liver cancer	0.000152	0.000824	CcSEcCtD
Valproic Acid—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—liver cancer	0.000152	0.000821	CcSEcCtD
Valproic Acid—Discomfort—Doxorubicin—liver cancer	0.000151	0.000817	CcSEcCtD
Valproic Acid—Anorexia—Epirubicin—liver cancer	0.000151	0.000816	CcSEcCtD
Valproic Acid—Dry mouth—Doxorubicin—liver cancer	0.000149	0.000808	CcSEcCtD
Valproic Acid—Hypotension—Epirubicin—liver cancer	0.000148	0.0008	CcSEcCtD
Valproic Acid—Confusional state—Doxorubicin—liver cancer	0.000148	0.000799	CcSEcCtD
Valproic Acid—Oedema—Doxorubicin—liver cancer	0.000146	0.000792	CcSEcCtD
Valproic Acid—Anaphylactic shock—Doxorubicin—liver cancer	0.000146	0.000792	CcSEcCtD
Valproic Acid—Infection—Doxorubicin—liver cancer	0.000145	0.000787	CcSEcCtD
Valproic Acid—Musculoskeletal discomfort—Epirubicin—liver cancer	0.000144	0.00078	CcSEcCtD
Valproic Acid—Nervous system disorder—Doxorubicin—liver cancer	0.000143	0.000777	CcSEcCtD
Valproic Acid—Thrombocytopenia—Doxorubicin—liver cancer	0.000143	0.000776	CcSEcCtD
Valproic Acid—Insomnia—Epirubicin—liver cancer	0.000143	0.000774	CcSEcCtD
Valproic Acid—Tachycardia—Doxorubicin—liver cancer	0.000143	0.000773	CcSEcCtD
Valproic Acid—Skin disorder—Doxorubicin—liver cancer	0.000142	0.00077	CcSEcCtD
Valproic Acid—Paraesthesia—Epirubicin—liver cancer	0.000142	0.000769	CcSEcCtD
Valproic Acid—Hyperhidrosis—Doxorubicin—liver cancer	0.000141	0.000766	CcSEcCtD
Valproic Acid—Dyspnoea—Epirubicin—liver cancer	0.000141	0.000763	CcSEcCtD
Valproic Acid—Somnolence—Epirubicin—liver cancer	0.000141	0.000761	CcSEcCtD
Valproic Acid—Anorexia—Doxorubicin—liver cancer	0.000139	0.000755	CcSEcCtD
Valproic Acid—Dyspepsia—Epirubicin—liver cancer	0.000139	0.000754	CcSEcCtD
Valproic Acid—Decreased appetite—Epirubicin—liver cancer	0.000137	0.000744	CcSEcCtD
Valproic Acid—Hypotension—Doxorubicin—liver cancer	0.000137	0.00074	CcSEcCtD
Valproic Acid—Gastrointestinal disorder—Epirubicin—liver cancer	0.000136	0.000739	CcSEcCtD
Valproic Acid—Fatigue—Epirubicin—liver cancer	0.000136	0.000738	CcSEcCtD
Valproic Acid—Constipation—Epirubicin—liver cancer	0.000135	0.000732	CcSEcCtD
Valproic Acid—Pain—Epirubicin—liver cancer	0.000135	0.000732	CcSEcCtD
Valproic Acid—Musculoskeletal discomfort—Doxorubicin—liver cancer	0.000133	0.000722	CcSEcCtD
Valproic Acid—Insomnia—Doxorubicin—liver cancer	0.000132	0.000717	CcSEcCtD
Valproic Acid—Paraesthesia—Doxorubicin—liver cancer	0.000131	0.000711	CcSEcCtD
Valproic Acid—Dyspnoea—Doxorubicin—liver cancer	0.00013	0.000706	CcSEcCtD
Valproic Acid—Feeling abnormal—Epirubicin—liver cancer	0.00013	0.000706	CcSEcCtD
Valproic Acid—Somnolence—Doxorubicin—liver cancer	0.00013	0.000704	CcSEcCtD
Valproic Acid—Gastrointestinal pain—Epirubicin—liver cancer	0.000129	0.0007	CcSEcCtD
Valproic Acid—Dyspepsia—Doxorubicin—liver cancer	0.000129	0.000697	CcSEcCtD
Valproic Acid—Decreased appetite—Doxorubicin—liver cancer	0.000127	0.000689	CcSEcCtD
Valproic Acid—Gastrointestinal disorder—Doxorubicin—liver cancer	0.000126	0.000684	CcSEcCtD
Valproic Acid—Fatigue—Doxorubicin—liver cancer	0.000126	0.000683	CcSEcCtD
Valproic Acid—Urticaria—Epirubicin—liver cancer	0.000126	0.00068	CcSEcCtD
Valproic Acid—Pain—Doxorubicin—liver cancer	0.000125	0.000678	CcSEcCtD
Valproic Acid—Constipation—Doxorubicin—liver cancer	0.000125	0.000678	CcSEcCtD
Valproic Acid—Abdominal pain—Epirubicin—liver cancer	0.000125	0.000677	CcSEcCtD
Valproic Acid—Body temperature increased—Epirubicin—liver cancer	0.000125	0.000677	CcSEcCtD
Valproic Acid—Feeling abnormal—Doxorubicin—liver cancer	0.000121	0.000653	CcSEcCtD
Valproic Acid—Gastrointestinal pain—Doxorubicin—liver cancer	0.00012	0.000648	CcSEcCtD
Valproic Acid—Hypersensitivity—Epirubicin—liver cancer	0.000116	0.000631	CcSEcCtD
Valproic Acid—Urticaria—Doxorubicin—liver cancer	0.000116	0.000629	CcSEcCtD
Valproic Acid—Body temperature increased—Doxorubicin—liver cancer	0.000116	0.000626	CcSEcCtD
Valproic Acid—Abdominal pain—Doxorubicin—liver cancer	0.000116	0.000626	CcSEcCtD
Valproic Acid—Asthenia—Epirubicin—liver cancer	0.000113	0.000614	CcSEcCtD
Valproic Acid—Pruritus—Epirubicin—liver cancer	0.000112	0.000606	CcSEcCtD
Valproic Acid—Diarrhoea—Epirubicin—liver cancer	0.000108	0.000586	CcSEcCtD
Valproic Acid—Hypersensitivity—Doxorubicin—liver cancer	0.000108	0.000584	CcSEcCtD
Valproic Acid—Asthenia—Doxorubicin—liver cancer	0.000105	0.000568	CcSEcCtD
Valproic Acid—Dizziness—Epirubicin—liver cancer	0.000105	0.000566	CcSEcCtD
Valproic Acid—Pruritus—Doxorubicin—liver cancer	0.000103	0.000561	CcSEcCtD
Valproic Acid—Vomiting—Epirubicin—liver cancer	0.000101	0.000544	CcSEcCtD
Valproic Acid—Diarrhoea—Doxorubicin—liver cancer	0.0001	0.000542	CcSEcCtD
Valproic Acid—Rash—Epirubicin—liver cancer	9.97e-05	0.00054	CcSEcCtD
Valproic Acid—Dermatitis—Epirubicin—liver cancer	9.96e-05	0.000539	CcSEcCtD
Valproic Acid—Headache—Epirubicin—liver cancer	9.9e-05	0.000536	CcSEcCtD
Valproic Acid—Dizziness—Doxorubicin—liver cancer	9.67e-05	0.000524	CcSEcCtD
Valproic Acid—Nausea—Epirubicin—liver cancer	9.39e-05	0.000509	CcSEcCtD
Valproic Acid—Vomiting—Doxorubicin—liver cancer	9.3e-05	0.000504	CcSEcCtD
Valproic Acid—Rash—Doxorubicin—liver cancer	9.22e-05	0.0005	CcSEcCtD
Valproic Acid—Dermatitis—Doxorubicin—liver cancer	9.22e-05	0.000499	CcSEcCtD
Valproic Acid—Headache—Doxorubicin—liver cancer	9.16e-05	0.000496	CcSEcCtD
Valproic Acid—Nausea—Doxorubicin—liver cancer	8.69e-05	0.000471	CcSEcCtD
Valproic Acid—HDAC9—Signaling Pathways—AKT1—liver cancer	7.24e-06	2.65e-05	CbGpPWpGaD
Valproic Acid—HDAC2—Signaling Pathways—PIK3CD—liver cancer	7.23e-06	2.65e-05	CbGpPWpGaD
Valproic Acid—PTGS1—Metabolism—CYP1A1—liver cancer	7.22e-06	2.64e-05	CbGpPWpGaD
Valproic Acid—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CD—liver cancer	7.21e-06	2.64e-05	CbGpPWpGaD
Valproic Acid—CYP2A6—Metabolism—GSTM1—liver cancer	7.2e-06	2.64e-05	CbGpPWpGaD
Valproic Acid—CYP2B6—Metabolism—CYCS—liver cancer	7.17e-06	2.63e-05	CbGpPWpGaD
Valproic Acid—HDAC2—Signaling Pathways—SERPINE1—liver cancer	7.15e-06	2.62e-05	CbGpPWpGaD
Valproic Acid—UGT2B15—Metabolism—AKT1—liver cancer	7.15e-06	2.62e-05	CbGpPWpGaD
Valproic Acid—CYP2C8—Metabolism of lipids and lipoproteins—ALB—liver cancer	7.11e-06	2.6e-05	CbGpPWpGaD
Valproic Acid—CYP2C19—Metabolism—HPGDS—liver cancer	7.1e-06	2.6e-05	CbGpPWpGaD
Valproic Acid—CYP2C8—Metabolism—PSMD10—liver cancer	7.09e-06	2.6e-05	CbGpPWpGaD
Valproic Acid—CYP2C8—Metabolism—PSMA4—liver cancer	7.09e-06	2.6e-05	CbGpPWpGaD
Valproic Acid—CYP2C19—Metabolism of lipids and lipoproteins—PPARG—liver cancer	7.06e-06	2.59e-05	CbGpPWpGaD
Valproic Acid—CYP2B6—Metabolism—GOT1—liver cancer	7.04e-06	2.58e-05	CbGpPWpGaD
Valproic Acid—CYP2B6—Metabolism—GGT1—liver cancer	7.04e-06	2.58e-05	CbGpPWpGaD
Valproic Acid—CYP3A5—Metabolism—CYCS—liver cancer	7.01e-06	2.57e-05	CbGpPWpGaD
Valproic Acid—CYP1A2—Metabolism—GSTA1—liver cancer	7e-06	2.56e-05	CbGpPWpGaD
Valproic Acid—HDAC2—Gene Expression—MYC—liver cancer	6.96e-06	2.55e-05	CbGpPWpGaD
Valproic Acid—HDAC2—Disease—STAT3—liver cancer	6.96e-06	2.55e-05	CbGpPWpGaD
Valproic Acid—UGT1A9—Metabolism—PIK3CG—liver cancer	6.93e-06	2.54e-05	CbGpPWpGaD
Valproic Acid—CYP1A2—Metabolism—NAT2—liver cancer	6.92e-06	2.53e-05	CbGpPWpGaD
Valproic Acid—CYP2C8—Metabolism—GOT2—liver cancer	6.9e-06	2.53e-05	CbGpPWpGaD
Valproic Acid—CYP3A5—Metabolism—GGT1—liver cancer	6.88e-06	2.52e-05	CbGpPWpGaD
Valproic Acid—CYP3A5—Metabolism—GOT1—liver cancer	6.88e-06	2.52e-05	CbGpPWpGaD
Valproic Acid—CYP2A6—Metabolism—CYP1A1—liver cancer	6.82e-06	2.5e-05	CbGpPWpGaD
Valproic Acid—PTGS1—Metabolism—MTHFR—liver cancer	6.73e-06	2.46e-05	CbGpPWpGaD
Valproic Acid—CYP2C18—Metabolism—PIK3CB—liver cancer	6.72e-06	2.46e-05	CbGpPWpGaD
Valproic Acid—UGT1A9—Metabolism—PPARG—liver cancer	6.69e-06	2.45e-05	CbGpPWpGaD
Valproic Acid—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CG—liver cancer	6.67e-06	2.44e-05	CbGpPWpGaD
Valproic Acid—CYP1A2—Metabolism of lipids and lipoproteins—PPARA—liver cancer	6.66e-06	2.44e-05	CbGpPWpGaD
Valproic Acid—CYP1A2—Metabolism—ALDOB—liver cancer	6.64e-06	2.43e-05	CbGpPWpGaD
Valproic Acid—CYP3A4—Metabolism—GLUL—liver cancer	6.63e-06	2.43e-05	CbGpPWpGaD
Valproic Acid—CYP3A4—Metabolism—CPT1B—liver cancer	6.63e-06	2.43e-05	CbGpPWpGaD
Valproic Acid—PTGS1—Metabolism—PPARA—liver cancer	6.6e-06	2.42e-05	CbGpPWpGaD
Valproic Acid—UGT2B7—Metabolism—PIK3CB—liver cancer	6.54e-06	2.39e-05	CbGpPWpGaD
Valproic Acid—CYP2C8—Metabolism—CYP2E1—liver cancer	6.49e-06	2.38e-05	CbGpPWpGaD
Valproic Acid—CYP2C9—Metabolism—HPGDS—liver cancer	6.48e-06	2.37e-05	CbGpPWpGaD
Valproic Acid—HDAC2—Disease—MYC—liver cancer	6.47e-06	2.37e-05	CbGpPWpGaD
Valproic Acid—HDAC2—Signaling Pathways—RAF1—liver cancer	6.46e-06	2.36e-05	CbGpPWpGaD
Valproic Acid—HDAC2—Disease—TGFB1—liver cancer	6.45e-06	2.36e-05	CbGpPWpGaD
Valproic Acid—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—liver cancer	6.44e-06	2.36e-05	CbGpPWpGaD
Valproic Acid—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CD—liver cancer	6.43e-06	2.36e-05	CbGpPWpGaD
Valproic Acid—CYP3A4—Metabolism—NR1H4—liver cancer	6.39e-06	2.34e-05	CbGpPWpGaD
Valproic Acid—CYP2A6—Metabolism—MTHFR—liver cancer	6.36e-06	2.33e-05	CbGpPWpGaD
Valproic Acid—CYP2C19—Metabolism of lipids and lipoproteins—ALB—liver cancer	6.35e-06	2.32e-05	CbGpPWpGaD
Valproic Acid—CYP1A2—Metabolism—CRABP1—liver cancer	6.33e-06	2.32e-05	CbGpPWpGaD
Valproic Acid—CYP2C19—Metabolism—PSMA4—liver cancer	6.33e-06	2.32e-05	CbGpPWpGaD
Valproic Acid—CYP2C19—Metabolism—PSMD10—liver cancer	6.33e-06	2.32e-05	CbGpPWpGaD
Valproic Acid—CYP2B6—Metabolism—GSTP1—liver cancer	6.32e-06	2.31e-05	CbGpPWpGaD
Valproic Acid—HDAC2—Signaling Pathways—MTOR—liver cancer	6.3e-06	2.31e-05	CbGpPWpGaD
Valproic Acid—HDAC2—Signaling Pathways—PIK3CB—liver cancer	6.3e-06	2.31e-05	CbGpPWpGaD
Valproic Acid—CYP3A4—Metabolism—GSTA3—liver cancer	6.28e-06	2.3e-05	CbGpPWpGaD
Valproic Acid—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CB—liver cancer	6.28e-06	2.3e-05	CbGpPWpGaD
Valproic Acid—CYP2A6—Metabolism—PPARA—liver cancer	6.24e-06	2.28e-05	CbGpPWpGaD
Valproic Acid—CYP2B6—Metabolism—HMOX1—liver cancer	6.23e-06	2.28e-05	CbGpPWpGaD
Valproic Acid—CYP3A5—Metabolism—GSTP1—liver cancer	6.18e-06	2.26e-05	CbGpPWpGaD
Valproic Acid—CYP2C19—Metabolism—GOT2—liver cancer	6.16e-06	2.25e-05	CbGpPWpGaD
Valproic Acid—UGT1A9—Metabolism—PIK3CD—liver cancer	6.09e-06	2.23e-05	CbGpPWpGaD
Valproic Acid—CYP3A5—Metabolism—HMOX1—liver cancer	6.09e-06	2.23e-05	CbGpPWpGaD
Valproic Acid—CYP2C8—Metabolism—CYCS—liver cancer	6.07e-06	2.22e-05	CbGpPWpGaD
Valproic Acid—UGT1A9—Metabolism—ALB—liver cancer	6.02e-06	2.2e-05	CbGpPWpGaD
Valproic Acid—HDAC2—Disease—KRAS—liver cancer	5.97e-06	2.19e-05	CbGpPWpGaD
Valproic Acid—UGT1A6—Metabolism—AKT1—liver cancer	5.97e-06	2.18e-05	CbGpPWpGaD
Valproic Acid—CYP2C8—Metabolism—GOT1—liver cancer	5.96e-06	2.18e-05	CbGpPWpGaD
Valproic Acid—CYP2C8—Metabolism—GGT1—liver cancer	5.96e-06	2.18e-05	CbGpPWpGaD
Valproic Acid—PTGS1—Metabolism of lipids and lipoproteins—PIK3CA—liver cancer	5.93e-06	2.17e-05	CbGpPWpGaD
Valproic Acid—HDAC2—Signaling Pathways—CDKN1B—liver cancer	5.92e-06	2.17e-05	CbGpPWpGaD
Valproic Acid—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CD—liver cancer	5.86e-06	2.15e-05	CbGpPWpGaD
Valproic Acid—CYP2B6—Metabolism—GSTM1—liver cancer	5.81e-06	2.13e-05	CbGpPWpGaD
Valproic Acid—HDAC2—Signaling Pathways—CASP3—liver cancer	5.8e-06	2.12e-05	CbGpPWpGaD
Valproic Acid—CYP2C19—Metabolism—CYP2E1—liver cancer	5.79e-06	2.12e-05	CbGpPWpGaD
Valproic Acid—HDAC2—Signaling Pathways—IL2—liver cancer	5.79e-06	2.12e-05	CbGpPWpGaD
Valproic Acid—CYP2C9—Metabolism of lipids and lipoproteins—ALB—liver cancer	5.79e-06	2.12e-05	CbGpPWpGaD
Valproic Acid—CYP2C9—Metabolism—PSMD10—liver cancer	5.77e-06	2.11e-05	CbGpPWpGaD
Valproic Acid—CYP2C9—Metabolism—PSMA4—liver cancer	5.77e-06	2.11e-05	CbGpPWpGaD
Valproic Acid—CYP3A4—Metabolism—GSTA4—liver cancer	5.75e-06	2.1e-05	CbGpPWpGaD
Valproic Acid—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CG—liver cancer	5.7e-06	2.09e-05	CbGpPWpGaD
Valproic Acid—CYP3A5—Metabolism—GSTM1—liver cancer	5.68e-06	2.08e-05	CbGpPWpGaD
Valproic Acid—PTGS1—Metabolism—PIK3CG—liver cancer	5.65e-06	2.07e-05	CbGpPWpGaD
Valproic Acid—HDAC2—Signaling Pathways—CCND1—liver cancer	5.64e-06	2.07e-05	CbGpPWpGaD
Valproic Acid—UGT1A4—Metabolism—PIK3CA—liver cancer	5.64e-06	2.06e-05	CbGpPWpGaD
Valproic Acid—HDAC2—Signaling Pathways—JUN—liver cancer	5.63e-06	2.06e-05	CbGpPWpGaD
Valproic Acid—CYP2C9—Metabolism—GOT2—liver cancer	5.62e-06	2.06e-05	CbGpPWpGaD
Valproic Acid—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CB—liver cancer	5.61e-06	2.05e-05	CbGpPWpGaD
Valproic Acid—CYP3A4—Metabolism—GSTA2—liver cancer	5.6e-06	2.05e-05	CbGpPWpGaD
Valproic Acid—HDAC2—Signaling Pathways—CTNNB1—liver cancer	5.59e-06	2.05e-05	CbGpPWpGaD
Valproic Acid—CYP1A2—Metabolism—HPGDS—liver cancer	5.53e-06	2.03e-05	CbGpPWpGaD
Valproic Acid—CYP2B6—Metabolism—CYP1A1—liver cancer	5.51e-06	2.02e-05	CbGpPWpGaD
Valproic Acid—CYP1A2—Metabolism of lipids and lipoproteins—PPARG—liver cancer	5.5e-06	2.01e-05	CbGpPWpGaD
Valproic Acid—HDAC2—Disease—PIK3CA—liver cancer	5.49e-06	2.01e-05	CbGpPWpGaD
Valproic Acid—HDAC2—Signaling Pathways—MMP9—liver cancer	5.48e-06	2.01e-05	CbGpPWpGaD
Valproic Acid—HDAC2—Signaling Pathways—CDKN1A—liver cancer	5.46e-06	2e-05	CbGpPWpGaD
Valproic Acid—PTGS1—Metabolism—PPARG—liver cancer	5.45e-06	2e-05	CbGpPWpGaD
Valproic Acid—CYP2C19—Metabolism—CYCS—liver cancer	5.42e-06	1.98e-05	CbGpPWpGaD
Valproic Acid—CYP3A4—Metabolism—GSTA1—liver cancer	5.4e-06	1.98e-05	CbGpPWpGaD
Valproic Acid—CYP3A5—Metabolism—CYP1A1—liver cancer	5.38e-06	1.97e-05	CbGpPWpGaD
Valproic Acid—CYP2C8—Metabolism—GSTP1—liver cancer	5.35e-06	1.96e-05	CbGpPWpGaD
Valproic Acid—CYP2A6—Metabolism—PIK3CG—liver cancer	5.34e-06	1.96e-05	CbGpPWpGaD
Valproic Acid—CYP3A4—Metabolism—NAT2—liver cancer	5.34e-06	1.96e-05	CbGpPWpGaD
Valproic Acid—HDAC2—Signaling Pathways—MAPK8—liver cancer	5.33e-06	1.95e-05	CbGpPWpGaD
Valproic Acid—CYP2C19—Metabolism—GOT1—liver cancer	5.32e-06	1.95e-05	CbGpPWpGaD
Valproic Acid—CYP2C19—Metabolism—GGT1—liver cancer	5.32e-06	1.95e-05	CbGpPWpGaD
Valproic Acid—UGT1A9—Metabolism—PIK3CB—liver cancer	5.31e-06	1.95e-05	CbGpPWpGaD
Valproic Acid—CYP2C9—Metabolism—CYP2E1—liver cancer	5.28e-06	1.93e-05	CbGpPWpGaD
Valproic Acid—CYP2C8—Metabolism—HMOX1—liver cancer	5.28e-06	1.93e-05	CbGpPWpGaD
Valproic Acid—CYP2A6—Metabolism—PPARG—liver cancer	5.16e-06	1.89e-05	CbGpPWpGaD
Valproic Acid—CYP2B6—Metabolism—MTHFR—liver cancer	5.13e-06	1.88e-05	CbGpPWpGaD
Valproic Acid—CYP3A4—Metabolism—ALDOB—liver cancer	5.12e-06	1.88e-05	CbGpPWpGaD
Valproic Acid—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CB—liver cancer	5.11e-06	1.87e-05	CbGpPWpGaD
Valproic Acid—HDAC2—Disease—HRAS—liver cancer	5.08e-06	1.86e-05	CbGpPWpGaD
Valproic Acid—CYP2B6—Metabolism—PPARA—liver cancer	5.03e-06	1.84e-05	CbGpPWpGaD
Valproic Acid—SLC16A1—Metabolism—PIK3CA—liver cancer	5.03e-06	1.84e-05	CbGpPWpGaD
Valproic Acid—CYP3A5—Metabolism—MTHFR—liver cancer	5.02e-06	1.84e-05	CbGpPWpGaD
Valproic Acid—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CD—liver cancer	5.01e-06	1.83e-05	CbGpPWpGaD
Valproic Acid—PTGS1—Metabolism—PIK3CD—liver cancer	4.97e-06	1.82e-05	CbGpPWpGaD
Valproic Acid—CYP1A2—Metabolism of lipids and lipoproteins—ALB—liver cancer	4.95e-06	1.81e-05	CbGpPWpGaD
Valproic Acid—CYP2C9—Metabolism—CYCS—liver cancer	4.94e-06	1.81e-05	CbGpPWpGaD
Valproic Acid—CYP1A2—Metabolism—PSMA4—liver cancer	4.93e-06	1.81e-05	CbGpPWpGaD
Valproic Acid—CYP1A2—Metabolism—PSMD10—liver cancer	4.93e-06	1.81e-05	CbGpPWpGaD
Valproic Acid—CYP3A5—Metabolism—PPARA—liver cancer	4.92e-06	1.8e-05	CbGpPWpGaD
Valproic Acid—HDAC2—Signaling Pathways—VEGFA—liver cancer	4.92e-06	1.8e-05	CbGpPWpGaD
Valproic Acid—CYP2C8—Metabolism—GSTM1—liver cancer	4.92e-06	1.8e-05	CbGpPWpGaD
Valproic Acid—PTGS1—Metabolism—ALB—liver cancer	4.9e-06	1.8e-05	CbGpPWpGaD
Valproic Acid—CYP3A4—Metabolism—CRABP1—liver cancer	4.89e-06	1.79e-05	CbGpPWpGaD
Valproic Acid—HDAC2—Signaling Pathways—STAT3—liver cancer	4.87e-06	1.78e-05	CbGpPWpGaD
Valproic Acid—HDAC2—Disease—IL6—liver cancer	4.86e-06	1.78e-05	CbGpPWpGaD
Valproic Acid—CYP2C9—Metabolism—GOT1—liver cancer	4.85e-06	1.77e-05	CbGpPWpGaD
Valproic Acid—CYP2C9—Metabolism—GGT1—liver cancer	4.85e-06	1.77e-05	CbGpPWpGaD
Valproic Acid—HDAC2—Gene Expression—AKT1—liver cancer	4.83e-06	1.77e-05	CbGpPWpGaD
Valproic Acid—CYP1A2—Metabolism—GOT2—liver cancer	4.8e-06	1.76e-05	CbGpPWpGaD
Valproic Acid—CYP2C19—Metabolism—GSTP1—liver cancer	4.78e-06	1.75e-05	CbGpPWpGaD
Valproic Acid—CYP2C19—Metabolism—HMOX1—liver cancer	4.71e-06	1.72e-05	CbGpPWpGaD
Valproic Acid—CYP2A6—Metabolism—PIK3CD—liver cancer	4.7e-06	1.72e-05	CbGpPWpGaD
Valproic Acid—UGT1A3—Metabolism—PIK3CA—liver cancer	4.69e-06	1.72e-05	CbGpPWpGaD
Valproic Acid—CYP2C8—Metabolism—CYP1A1—liver cancer	4.66e-06	1.71e-05	CbGpPWpGaD
Valproic Acid—CYP2A6—Metabolism—ALB—liver cancer	4.64e-06	1.7e-05	CbGpPWpGaD
Valproic Acid—UGT1A4—Metabolism—AKT1—liver cancer	4.61e-06	1.69e-05	CbGpPWpGaD
Valproic Acid—HDAC2—Signaling Pathways—MYC—liver cancer	4.53e-06	1.66e-05	CbGpPWpGaD
Valproic Acid—HDAC2—Signaling Pathways—TGFB1—liver cancer	4.52e-06	1.65e-05	CbGpPWpGaD
Valproic Acid—CYP1A2—Metabolism—CYP2E1—liver cancer	4.51e-06	1.65e-05	CbGpPWpGaD
Valproic Acid—HDAC2—Disease—AKT1—liver cancer	4.48e-06	1.64e-05	CbGpPWpGaD
Valproic Acid—CYP2C19—Metabolism—GSTM1—liver cancer	4.39e-06	1.61e-05	CbGpPWpGaD
Valproic Acid—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CB—liver cancer	4.37e-06	1.6e-05	CbGpPWpGaD
Valproic Acid—CYP2C9—Metabolism—GSTP1—liver cancer	4.35e-06	1.59e-05	CbGpPWpGaD
Valproic Acid—CYP2C8—Metabolism—MTHFR—liver cancer	4.34e-06	1.59e-05	CbGpPWpGaD
Valproic Acid—PTGS1—Metabolism—PIK3CB—liver cancer	4.33e-06	1.59e-05	CbGpPWpGaD
Valproic Acid—CYP2B6—Metabolism—PIK3CG—liver cancer	4.31e-06	1.58e-05	CbGpPWpGaD
Valproic Acid—CYP2C9—Metabolism—HMOX1—liver cancer	4.29e-06	1.57e-05	CbGpPWpGaD
Valproic Acid—CYP3A4—Metabolism—HPGDS—liver cancer	4.27e-06	1.56e-05	CbGpPWpGaD
Valproic Acid—CYP2C8—Metabolism—PPARA—liver cancer	4.26e-06	1.56e-05	CbGpPWpGaD
Valproic Acid—CYP1A2—Metabolism—CYCS—liver cancer	4.22e-06	1.55e-05	CbGpPWpGaD
Valproic Acid—CYP3A5—Metabolism—PIK3CG—liver cancer	4.21e-06	1.54e-05	CbGpPWpGaD
Valproic Acid—HDAC2—Signaling Pathways—KRAS—liver cancer	4.18e-06	1.53e-05	CbGpPWpGaD
Valproic Acid—CYP2B6—Metabolism—PPARG—liver cancer	4.16e-06	1.52e-05	CbGpPWpGaD
Valproic Acid—CYP2C19—Metabolism—CYP1A1—liver cancer	4.16e-06	1.52e-05	CbGpPWpGaD
Valproic Acid—CYP1A2—Metabolism—GOT1—liver cancer	4.14e-06	1.52e-05	CbGpPWpGaD
Valproic Acid—CYP1A2—Metabolism—GGT1—liver cancer	4.14e-06	1.52e-05	CbGpPWpGaD
Valproic Acid—SLC16A1—Metabolism—AKT1—liver cancer	4.11e-06	1.5e-05	CbGpPWpGaD
Valproic Acid—CYP2C18—Metabolism—PIK3CA—liver cancer	4.1e-06	1.5e-05	CbGpPWpGaD
Valproic Acid—CYP2A6—Metabolism—PIK3CB—liver cancer	4.1e-06	1.5e-05	CbGpPWpGaD
Valproic Acid—CYP3A5—Metabolism—PPARG—liver cancer	4.07e-06	1.49e-05	CbGpPWpGaD
Valproic Acid—CYP2C9—Metabolism—GSTM1—liver cancer	4e-06	1.47e-05	CbGpPWpGaD
Valproic Acid—UGT2B7—Metabolism—PIK3CA—liver cancer	3.99e-06	1.46e-05	CbGpPWpGaD
Valproic Acid—CYP2C19—Metabolism—MTHFR—liver cancer	3.88e-06	1.42e-05	CbGpPWpGaD
Valproic Acid—HDAC2—Signaling Pathways—PIK3CA—liver cancer	3.84e-06	1.41e-05	CbGpPWpGaD
Valproic Acid—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CA—liver cancer	3.83e-06	1.4e-05	CbGpPWpGaD
Valproic Acid—UGT1A3—Metabolism—AKT1—liver cancer	3.83e-06	1.4e-05	CbGpPWpGaD
Valproic Acid—CYP3A4—Metabolism—PSMA4—liver cancer	3.81e-06	1.39e-05	CbGpPWpGaD
Valproic Acid—CYP3A4—Metabolism—PSMD10—liver cancer	3.81e-06	1.39e-05	CbGpPWpGaD
Valproic Acid—CYP2C19—Metabolism—PPARA—liver cancer	3.8e-06	1.39e-05	CbGpPWpGaD
Valproic Acid—CYP2C9—Metabolism—CYP1A1—liver cancer	3.79e-06	1.39e-05	CbGpPWpGaD
Valproic Acid—CYP2B6—Metabolism—PIK3CD—liver cancer	3.79e-06	1.39e-05	CbGpPWpGaD
Valproic Acid—CYP2B6—Metabolism—ALB—liver cancer	3.74e-06	1.37e-05	CbGpPWpGaD
Valproic Acid—CYP1A2—Metabolism—GSTP1—liver cancer	3.72e-06	1.36e-05	CbGpPWpGaD
Valproic Acid—HDAC2—Signaling Pathways—TP53—liver cancer	3.72e-06	1.36e-05	CbGpPWpGaD
Valproic Acid—CYP3A5—Metabolism—PIK3CD—liver cancer	3.71e-06	1.36e-05	CbGpPWpGaD
Valproic Acid—CYP3A4—Metabolism—GOT2—liver cancer	3.7e-06	1.36e-05	CbGpPWpGaD
Valproic Acid—CYP1A2—Metabolism—HMOX1—liver cancer	3.67e-06	1.34e-05	CbGpPWpGaD
Valproic Acid—CYP3A5—Metabolism—ALB—liver cancer	3.66e-06	1.34e-05	CbGpPWpGaD
Valproic Acid—CYP2C8—Metabolism—PIK3CG—liver cancer	3.65e-06	1.34e-05	CbGpPWpGaD
Valproic Acid—HDAC2—Signaling Pathways—HRAS—liver cancer	3.56e-06	1.3e-05	CbGpPWpGaD
Valproic Acid—CYP2C9—Metabolism—MTHFR—liver cancer	3.54e-06	1.29e-05	CbGpPWpGaD
Valproic Acid—CYP2C8—Metabolism—PPARG—liver cancer	3.52e-06	1.29e-05	CbGpPWpGaD
Valproic Acid—CYP3A4—Metabolism—CYP2E1—liver cancer	3.48e-06	1.27e-05	CbGpPWpGaD
Valproic Acid—CYP2C9—Metabolism—PPARA—liver cancer	3.47e-06	1.27e-05	CbGpPWpGaD
Valproic Acid—CYP1A2—Metabolism—GSTM1—liver cancer	3.42e-06	1.25e-05	CbGpPWpGaD
Valproic Acid—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CA—liver cancer	3.42e-06	1.25e-05	CbGpPWpGaD
Valproic Acid—HDAC2—Signaling Pathways—IL6—liver cancer	3.4e-06	1.25e-05	CbGpPWpGaD
Valproic Acid—CYP2C18—Metabolism—AKT1—liver cancer	3.35e-06	1.23e-05	CbGpPWpGaD
Valproic Acid—CYP2B6—Metabolism—PIK3CB—liver cancer	3.3e-06	1.21e-05	CbGpPWpGaD
Valproic Acid—CYP2C19—Metabolism—PIK3CG—liver cancer	3.26e-06	1.19e-05	CbGpPWpGaD
Valproic Acid—CYP3A4—Metabolism—CYCS—liver cancer	3.26e-06	1.19e-05	CbGpPWpGaD
Valproic Acid—UGT2B7—Metabolism—AKT1—liver cancer	3.26e-06	1.19e-05	CbGpPWpGaD
Valproic Acid—CYP1A2—Metabolism—CYP1A1—liver cancer	3.24e-06	1.19e-05	CbGpPWpGaD
Valproic Acid—UGT1A9—Metabolism—PIK3CA—liver cancer	3.24e-06	1.19e-05	CbGpPWpGaD
Valproic Acid—CYP3A5—Metabolism—PIK3CB—liver cancer	3.23e-06	1.18e-05	CbGpPWpGaD
Valproic Acid—CYP2C8—Metabolism—PIK3CD—liver cancer	3.21e-06	1.18e-05	CbGpPWpGaD
Valproic Acid—CYP3A4—Metabolism—GGT1—liver cancer	3.2e-06	1.17e-05	CbGpPWpGaD
Valproic Acid—CYP3A4—Metabolism—GOT1—liver cancer	3.2e-06	1.17e-05	CbGpPWpGaD
Valproic Acid—CYP2C8—Metabolism—ALB—liver cancer	3.17e-06	1.16e-05	CbGpPWpGaD
Valproic Acid—CYP2C19—Metabolism—PPARG—liver cancer	3.14e-06	1.15e-05	CbGpPWpGaD
Valproic Acid—HDAC2—Signaling Pathways—AKT1—liver cancer	3.14e-06	1.15e-05	CbGpPWpGaD
Valproic Acid—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—liver cancer	3.12e-06	1.14e-05	CbGpPWpGaD
Valproic Acid—CYP1A2—Metabolism—MTHFR—liver cancer	3.02e-06	1.11e-05	CbGpPWpGaD
Valproic Acid—CYP2C9—Metabolism—PIK3CG—liver cancer	2.97e-06	1.09e-05	CbGpPWpGaD
Valproic Acid—CYP1A2—Metabolism—PPARA—liver cancer	2.96e-06	1.09e-05	CbGpPWpGaD
Valproic Acid—CYP3A4—Metabolism—GSTP1—liver cancer	2.87e-06	1.05e-05	CbGpPWpGaD
Valproic Acid—CYP2C9—Metabolism—PPARG—liver cancer	2.87e-06	1.05e-05	CbGpPWpGaD
Valproic Acid—CYP2C19—Metabolism—PIK3CD—liver cancer	2.86e-06	1.05e-05	CbGpPWpGaD
Valproic Acid—CYP3A4—Metabolism—HMOX1—liver cancer	2.83e-06	1.04e-05	CbGpPWpGaD
Valproic Acid—CYP2C19—Metabolism—ALB—liver cancer	2.83e-06	1.04e-05	CbGpPWpGaD
Valproic Acid—CYP2C8—Metabolism—PIK3CB—liver cancer	2.8e-06	1.02e-05	CbGpPWpGaD
Valproic Acid—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—liver cancer	2.66e-06	9.75e-06	CbGpPWpGaD
Valproic Acid—UGT1A9—Metabolism—AKT1—liver cancer	2.65e-06	9.69e-06	CbGpPWpGaD
Valproic Acid—PTGS1—Metabolism—PIK3CA—liver cancer	2.64e-06	9.67e-06	CbGpPWpGaD
Valproic Acid—CYP3A4—Metabolism—GSTM1—liver cancer	2.64e-06	9.66e-06	CbGpPWpGaD
Valproic Acid—CYP2C9—Metabolism—PIK3CD—liver cancer	2.61e-06	9.56e-06	CbGpPWpGaD
Valproic Acid—CYP2C9—Metabolism—ALB—liver cancer	2.58e-06	9.44e-06	CbGpPWpGaD
Valproic Acid—CYP1A2—Metabolism—PIK3CG—liver cancer	2.54e-06	9.3e-06	CbGpPWpGaD
Valproic Acid—CYP3A4—Metabolism—CYP1A1—liver cancer	2.5e-06	9.16e-06	CbGpPWpGaD
Valproic Acid—CYP2C19—Metabolism—PIK3CB—liver cancer	2.5e-06	9.14e-06	CbGpPWpGaD
Valproic Acid—CYP2A6—Metabolism—PIK3CA—liver cancer	2.5e-06	9.14e-06	CbGpPWpGaD
Valproic Acid—CYP1A2—Metabolism—PPARG—liver cancer	2.45e-06	8.97e-06	CbGpPWpGaD
Valproic Acid—CYP3A4—Metabolism—MTHFR—liver cancer	2.33e-06	8.54e-06	CbGpPWpGaD
Valproic Acid—CYP3A4—Metabolism—PPARA—liver cancer	2.29e-06	8.38e-06	CbGpPWpGaD
Valproic Acid—CYP2C9—Metabolism—PIK3CB—liver cancer	2.28e-06	8.34e-06	CbGpPWpGaD
Valproic Acid—CYP1A2—Metabolism—PIK3CD—liver cancer	2.23e-06	8.17e-06	CbGpPWpGaD
Valproic Acid—CYP1A2—Metabolism—ALB—liver cancer	2.2e-06	8.07e-06	CbGpPWpGaD
Valproic Acid—PTGS1—Metabolism—AKT1—liver cancer	2.16e-06	7.9e-06	CbGpPWpGaD
Valproic Acid—CYP2A6—Metabolism—AKT1—liver cancer	2.04e-06	7.47e-06	CbGpPWpGaD
Valproic Acid—CYP2B6—Metabolism—PIK3CA—liver cancer	2.01e-06	7.37e-06	CbGpPWpGaD
Valproic Acid—CYP3A5—Metabolism—PIK3CA—liver cancer	1.97e-06	7.21e-06	CbGpPWpGaD
Valproic Acid—CYP3A4—Metabolism—PIK3CG—liver cancer	1.96e-06	7.17e-06	CbGpPWpGaD
Valproic Acid—CYP1A2—Metabolism—PIK3CB—liver cancer	1.95e-06	7.12e-06	CbGpPWpGaD
Valproic Acid—CYP3A4—Metabolism—PPARG—liver cancer	1.89e-06	6.92e-06	CbGpPWpGaD
Valproic Acid—CYP3A4—Metabolism—PIK3CD—liver cancer	1.72e-06	6.31e-06	CbGpPWpGaD
Valproic Acid—CYP2C8—Metabolism—PIK3CA—liver cancer	1.71e-06	6.24e-06	CbGpPWpGaD
Valproic Acid—CYP3A4—Metabolism—ALB—liver cancer	1.7e-06	6.23e-06	CbGpPWpGaD
Valproic Acid—CYP2B6—Metabolism—AKT1—liver cancer	1.65e-06	6.02e-06	CbGpPWpGaD
Valproic Acid—CYP3A5—Metabolism—AKT1—liver cancer	1.61e-06	5.89e-06	CbGpPWpGaD
Valproic Acid—CYP2C19—Metabolism—PIK3CA—liver cancer	1.52e-06	5.57e-06	CbGpPWpGaD
Valproic Acid—CYP3A4—Metabolism—PIK3CB—liver cancer	1.5e-06	5.5e-06	CbGpPWpGaD
Valproic Acid—CYP2C8—Metabolism—AKT1—liver cancer	1.39e-06	5.1e-06	CbGpPWpGaD
Valproic Acid—CYP2C9—Metabolism—PIK3CA—liver cancer	1.39e-06	5.08e-06	CbGpPWpGaD
Valproic Acid—CYP2C19—Metabolism—AKT1—liver cancer	1.24e-06	4.55e-06	CbGpPWpGaD
Valproic Acid—CYP1A2—Metabolism—PIK3CA—liver cancer	1.19e-06	4.34e-06	CbGpPWpGaD
Valproic Acid—CYP2C9—Metabolism—AKT1—liver cancer	1.13e-06	4.15e-06	CbGpPWpGaD
Valproic Acid—CYP1A2—Metabolism—AKT1—liver cancer	9.69e-07	3.55e-06	CbGpPWpGaD
Valproic Acid—CYP3A4—Metabolism—PIK3CA—liver cancer	9.15e-07	3.35e-06	CbGpPWpGaD
Valproic Acid—CYP3A4—Metabolism—AKT1—liver cancer	7.48e-07	2.74e-06	CbGpPWpGaD
